Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading


Drug Treatments for Skin Disease Introduced in 2005

Drug Class

Generic/Trade
Company Names

Indication

Approving
Regulatory Agency

Antiaging Treatments

Clindamycin Foam 1%
Aluma®Skin Renewal System with FACES™
Lumenis

Approved for the noninvasive treatment of fine lines and wrinkles.

US FDA

Antibacterial Agents

Meropenem for Injection
MERREM®
AstraZeneca

Approved for the noninvasive treatment of fine lines and wrinkles.

US FDA

Moxifloxacin HCl
Avelox®
Bayer HealthCare Schering-Plough

Approved for the treatment of complicated skin and skin structure infections in adults and children.

US FDA

Tygacycline
Tygacil®
Wyeth

Approved for the treatment of complicated skin and skin structure infections in adults that are caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.

US FDA
EMEA

Antifungal Agents

Ciclopirox Topical Suspension 0.77%
Taro Pharmaceuticals

Abbreviated NDA approved for the treatment of fungal infections of the skin. It is the bioequivalent of Medicis Pharmaceutical’s Loprox® Topical Suspension 0.77%.

US FDA

Griseofulvin Oral Suspension USP
Glades Pharmaceuticals

Approved for the treatment of tinea barbae, tinea capitis, tinea corporis, tinea pedis, and tinea unguium (onychomycosis).

US FDA

Terbinafine HCl
Lamisil®Tablets
Ranbaxy Laboratories

Approved for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).

US FDA

Antihistamine

Desloratadine Syrup
Clarinex®Reditabs®
Schering-Plough

Reformulated 2.5mg and 5mg tablets approved for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and for chronic idiopathic urticaria, or hives of unknown cause, in adults and children >6 years of age.

US FDA

Antipruritic Agents

Epinastine HCl 1%
Alesion®Dry Syrup
Nippon Boehringer Ingelheim/ Sankyo

Approved for the treatment of allergic rhinitis, urticaria, and pruritus associated with skin diseases such as eczema and dermatitis in pediatric patients.

Japanese Ministry of Health, Labour and Welfare

Antipsoriatic Agents

Clobetasol Propionate 0.05%
Clobex™Spray
Galderma

For the treatment of moderate-to-severe plaque psoriasis. Clobex® is already available as a lotion and shampoo.

US FDA

Efalizumab
Raptiva®
Serono

Approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults >18 years of age who are candidates for systemic therapy or phototherapy.

TPD Canada

Etanercept
Enbrel®
Amgen/ Wyeth Pharmaceuticals

Approved for the treatment of moderate-to-severe psoriasis in adults.

TPD Canada

Fluocinonide 0.1%
Vanos®
Cream Medicis Pharmaceuticals

A new class I topical corticosteroid approved for the treatment of plaque-type psoriasis affecting up to 10% of the body surface area.

US FDA

Infliximab
Remicade®
Centocor/ Schering-Plough

Approved for the treatment of moderate-to-severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapies including cyclosporine, methotrexate, or PUVA.

EMEA

Atopic Dermatitis Agents

Fluticasone Propionate 0.05%
Cutivate®Lotion
Pharmaderm/Altana

Approved in patients >1 year of age for the treatment of atopic dermatitis.

US FDA

Hydrogel Dressing
MimyX®Cream
Stiefel Laboratories

A topical nonsteroidal cream approved for the treatment of atopic dermatitis.

US FDA

HIV/AIDS

Emtricitabine
Emtriva™Oral Solution
Gilead Sciences

Approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients >3 months of age.

US FDA

Tipranavir Capsule
Aptivus®
Boehringer Ingelheim Pharmaceuticals

Accelerated approval for this nonpeptide protease inhibitor as a combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, and who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. The approved dose is 500mg taken with 200mg ritonavir twice daily

US FDA
EMEA

Leishmaniasis

Miltefosine
Impavido™
AEterna Zantaris

Approved for the treatment of the cutaneous form of leishmaniasis as well as the visceral form of this condition.

Columbian Food and Drug Agency

Oncologic Agents

Imiquimod 5%
Aldara™Cream
3M

Approved for the treatment of superficial basal cell carcinoma.

TPD Canada

Psoriatic Arthritis Agents

Adalimumab
Humira™
Abbott Laboratories

Approved for the treatment of psoriatic arthritis.

US FDA

Etanercept
Enbrel®
Amgen/ Wyeth Pharmaceuticals

Approved for the improvement of physical function in patients with psoriatic arthritis.

US FDA

Infliximab
Remicade®
Centocor/ Schering-Plough

Approved for the treatment of psoriatic arthritis.

US FDA

Rosacea

Metronidazole Topical Gel 1%
MetroGel®
Galderma Laboratories LP

Approved for the topical treatment of inflammatory lesions of rosacea.

US FDA

Vaccines

Measles, Mumps, Rubella, and Varicella Virus Vaccine, Live
ProQuad®
Merck

Approved for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age.

US FDA
EMEA

Wound Management

Antimicrobial Barrier Dressing
ACTICOAT*
Moisture Control Smith & Nephew

Approved for wound care as a barrier to bacterial penetration, featuring the patented Silcryst™ nanocrystalline silver technology.

US FDA


  1. A Practical Guide to Dermatological Drug Use in Pregnancy
  2. Drug Treatments for Skin Disease Introduced in 2005
  3. Update on Drugs and Drug News - May 2006